MY148457A - Combination preparations comprising slv308 and a dopamine agonist - Google Patents
Combination preparations comprising slv308 and a dopamine agonistInfo
- Publication number
- MY148457A MY148457A MYPI20085078A MYPI20085078A MY148457A MY 148457 A MY148457 A MY 148457A MY PI20085078 A MYPI20085078 A MY PI20085078A MY PI20085078 A MYPI20085078 A MY PI20085078A MY 148457 A MY148457 A MY 148457A
- Authority
- MY
- Malaysia
- Prior art keywords
- slv308
- dopamine agonist
- combination preparations
- acceptable salt
- pharmacologically acceptable
- Prior art date
Links
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- YVPUUUDAZYFFQT-UHFFFAOYSA-N 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one Chemical compound C1CN(C)CCN1C1=CC=CC2=C1OC(=O)N2 YVPUUUDAZYFFQT-UHFFFAOYSA-N 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000010249 dopaminergic function Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A COMPOSITION CONTAINING SLV308 OR ITS N-OXIDE, OR AT LEAST ONE PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF: AND L-DOPA OR AT LEAST ONE PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, FOR SIMULTANEOUS, SEPARATE OR SEQUENTIAL USE IN THE TREATMENT OF DISORDERS REQUIRING RECOVERY OF DOPAMINERGIC FUNCTION USING THIS COMPOSITION, INCLUDING PARKINSON'S DISEASE AND RESTLESS LEG SYNDROME.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81405106P | 2006-06-16 | 2006-06-16 | |
EP06115583 | 2006-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY148457A true MY148457A (en) | 2013-04-30 |
Family
ID=38434785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI20085078A MY148457A (en) | 2006-06-16 | 2007-06-15 | Combination preparations comprising slv308 and a dopamine agonist |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2035002A1 (en) |
JP (1) | JP2009539941A (en) |
KR (1) | KR20090031908A (en) |
AU (1) | AU2007259255A1 (en) |
CA (1) | CA2654719A1 (en) |
EA (1) | EA015073B1 (en) |
IL (1) | IL195532A0 (en) |
MY (1) | MY148457A (en) |
NO (1) | NO20090164L (en) |
WO (1) | WO2007144421A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0027020D0 (en) | 2000-11-03 | 2000-12-20 | Univ Manchester | Treatment of movement disorders |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7596407B2 (en) * | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
WO2006032202A1 (en) * | 2004-09-21 | 2006-03-30 | Shandong Luye Pharmaceutical Co., Ltd. | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
EP1919883B1 (en) * | 2005-08-22 | 2008-12-17 | Solvay Pharmaceuticals B.V. | N-oxides as prodrugs of piperazine&piperidine derivatives |
-
2007
- 2007-06-15 WO PCT/EP2007/055955 patent/WO2007144421A1/en active Search and Examination
- 2007-06-15 CA CA002654719A patent/CA2654719A1/en not_active Abandoned
- 2007-06-15 MY MYPI20085078A patent/MY148457A/en unknown
- 2007-06-15 KR KR1020097001024A patent/KR20090031908A/en not_active Application Discontinuation
- 2007-06-15 JP JP2009514809A patent/JP2009539941A/en active Pending
- 2007-06-15 EA EA200970021A patent/EA015073B1/en not_active IP Right Cessation
- 2007-06-15 AU AU2007259255A patent/AU2007259255A1/en not_active Abandoned
- 2007-06-15 EP EP07730193A patent/EP2035002A1/en not_active Withdrawn
-
2008
- 2008-11-26 IL IL195532A patent/IL195532A0/en unknown
-
2009
- 2009-01-12 NO NO20090164A patent/NO20090164L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2007144421A1 (en) | 2007-12-21 |
IL195532A0 (en) | 2009-09-01 |
EA200970021A1 (en) | 2009-06-30 |
CA2654719A1 (en) | 2007-12-21 |
KR20090031908A (en) | 2009-03-30 |
NO20090164L (en) | 2009-01-14 |
AU2007259255A1 (en) | 2007-12-21 |
EA015073B1 (en) | 2011-04-29 |
JP2009539941A (en) | 2009-11-19 |
EP2035002A1 (en) | 2009-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU93321I2 (en) | IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
MX2020012868A (en) | Methods and compositions for sleep disorders and other disorders. | |
TWI320316B (en) | Methods for inhibiting hscd activity,pyridazine derivatives and use and pharmaceutical composition thereof | |
IL186200A (en) | Use of amylin and amylin agonists, analogs and derivatives for the preparation of medicaments for treating psychiatric diseases | |
MX2009011359A (en) | Pyrimidinone derivatives and methods of use thereof. | |
MX2009011358A (en) | Pyrimidinone derivatives and methods of use thereof. | |
IL195256A0 (en) | Compositions of r(+)and s(-)pramipexole and methods of using the same | |
WO2009091576A3 (en) | Parenteral formulations of dopamine agonists | |
MX2010004450A (en) | Bicyclic heterocycle derivatives and methods of use thereof. | |
CL2012000702A1 (en) | Use of an alpha-7 nicotinic acetylcholine receptor agonist for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's disease. | |
SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
TNSN08326A1 (en) | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
UA97795C2 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
MX2009011357A (en) | Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof. | |
MY149854A (en) | Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | |
EP1261340A4 (en) | Compositions and methods for the treatment of parkinson's disease | |
ME01192B (en) | N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use | |
TW200801022A (en) | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments | |
WO2004069146A3 (en) | L-dopa amide derivatives and uses thereof | |
WO2009068708A3 (en) | Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof | |
EA202091356A1 (en) | A2a ANTAGONISTS AS AMPLIFIERS OF Cognitive and motor functions | |
CL2007001517A1 (en) | Compounds derived from carboxamide; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound for the treatment of pain, in therapy of functional gastrointestinal disorders, irritable bowel syndrome, cancer, parkinson's, Alzheimer's, cardiovascular disorders. | |
WO2007144422A3 (en) | Combination preparations comprising bifeprunox and l-dopa | |
CL2007000789A1 (en) | Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease. | |
WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |